Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHsMichael Dougan, Stephanie K. Dougan, Jessica R. Ingram et al.|Cancer Immunology Research|2018Cited by 82
1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%Mark M. Awad, P. Rietschel, F. Seebach et al.|Annals of Oncology|2023Cited by 4